Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alignment of PrEP Use With HIV Risk in Young Women and Men
NCT04664998Phase 4Completed
- Sponsor
- University of Washington
- Start
- May 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Washington. Primary endpoints: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms at 6 months and Visits With PrEP Dispensation to Male Study Participants Reporting Sexual Behaviors or STI Symptoms at 6 months. Started May 2018; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04664998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04664998.